patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_572238 | REC_0016401 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 16.7 | 81 | female | 1 | 16 | 5.9 | 1 | entrectinib 600 mg daily | 22 | false | MSI-H | 2026-03-15T05:36:01.726827+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_369252 | REC_0016402 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.9 | 68 | female | 0 | 18 | 7 | 5 | alectinib 600 mg BID | 11.1 | false | MSS | 2026-03-15T05:36:01.727207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_776353 | REC_0016403 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 17.1 | 69 | female | 1 | 17 | 5.7 | 2 | sotorasib 960 mg daily | 20.6 | true | MSI-H | 2026-03-15T05:36:01.727566+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454728 | REC_0016404 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 6 | 52 | male | 0 | 13 | 4.7 | 2 | pembrolizumab 200 mg q3w | 10.2 | true | MSS | 2026-03-15T05:36:01.727935+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363662 | REC_0016405 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 3.3 | 61 | male | 1 | 20 | 7.4 | 8 | carboplatin + paclitaxel + pembrolizumab | 10.9 | false | MSS | 2026-03-15T05:36:01.728405+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413879 | REC_0016406 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 12.9 | 69 | female | 1 | 22 | 6.7 | 1 | sotorasib 960 mg daily | 21.5 | false | MSS | 2026-03-15T05:36:01.728823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_564856 | REC_0016407 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 7.5 | 68 | female | 1 | 31 | 4.3 | 5 | osimertinib 80 mg daily | 7.8 | true | MSS | 2026-03-15T05:36:01.729280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_914604 | REC_0016408 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 18 | 7.4 | 77 | female | 2 | 11 | 6.1 | 4 | pembrolizumab 200 mg q3w | 7 | false | MSS | 2026-03-15T05:36:01.729586+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_230849 | REC_0016409 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 16 | 13.2 | 68 | female | 1 | 6 | 5.2 | 2 | entrectinib 600 mg daily | 16.2 | false | MSI-H | 2026-03-15T05:36:01.729885+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670808 | REC_0016410 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 9.3 | 73 | female | 3 | 10 | 4.6 | 7 | sotorasib 960 mg daily | 11.1 | false | MSS | 2026-03-15T05:36:01.730200+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_972786 | REC_0016411 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 9.4 | 57 | female | 1 | 10 | 6.1 | 3 | entrectinib 600 mg daily | 15.1 | false | MSS | 2026-03-15T05:36:01.730525+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_985693 | REC_0016412 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 11.4 | 60 | female | 1 | 12 | 8.5 | 6 | entrectinib 600 mg daily | 15.2 | false | MSS | 2026-03-15T05:36:01.730845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_754206 | REC_0016413 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 13.7 | 61 | female | 1 | 18 | 4.8 | 7 | entrectinib 600 mg daily | 11.7 | false | MSS | 2026-03-15T05:36:01.731170+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752859 | REC_0016414 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 9.4 | 72 | male | 2 | 8 | 4.8 | 2 | sotorasib 960 mg daily | 4 | true | MSS | 2026-03-15T05:36:01.731482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_740015 | REC_0016415 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.8 | 58 | male | 1 | 19 | 4.7 | 8 | carboplatin + paclitaxel + pembrolizumab | 10.2 | false | MSS | 2026-03-15T05:36:01.731848+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557045 | REC_0016416 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 12.1 | 62 | male | 1 | 22 | 7.5 | 2 | osimertinib 80 mg daily | 12 | false | MSI-H | 2026-03-15T05:36:01.732337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_627548 | REC_0016417 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 12.6 | 73 | female | 1 | 17 | 6.9 | 7 | osimertinib 80 mg daily | 12.1 | false | MSS | 2026-03-15T05:36:01.732771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_444892 | REC_0016418 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 16 | 74 | female | 2 | 19 | 5.1 | 2 | alectinib 600 mg BID | 27.8 | false | MSI-H | 2026-03-15T05:36:01.733163+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927427 | REC_0016419 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 13.9 | 74 | female | 2 | 17 | 4.8 | 6 | osimertinib 80 mg daily | 7.9 | true | MSI-H | 2026-03-15T05:36:01.733505+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831407 | REC_0016420 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 11.5 | 66 | female | 1 | 27 | 6.2 | 6 | alectinib 600 mg BID | 15.5 | true | MSI-H | 2026-03-15T05:36:01.734054+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_661339 | REC_0016421 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 21 | 4.7 | 59 | female | 0 | 9 | 5.4 | 2 | pembrolizumab 200 mg q3w | 13.5 | false | MSS | 2026-03-15T05:36:01.734462+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_908203 | REC_0016422 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 7.7 | 59 | male | 0 | 4 | 5.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.7 | false | MSS | 2026-03-15T05:36:01.734816+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140650 | REC_0016423 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13.3 | 52 | female | 0 | 17 | 5 | 8 | entrectinib 600 mg daily | 14.6 | false | MSS | 2026-03-15T05:36:01.735186+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_369667 | REC_0016424 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 8.8 | 90 | female | 2 | 14 | 4.4 | 4 | sotorasib 960 mg daily | 8.9 | true | MSS | 2026-03-15T05:36:01.735546+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_769035 | REC_0016425 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 11.1 | 77 | female | 1 | 7 | 5.7 | 5 | entrectinib 600 mg daily | 5.5 | false | MSI-H | 2026-03-15T05:36:01.735897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_740051 | REC_0016426 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 5.9 | 49 | female | 0 | 17 | 5.5 | 0 | osimertinib 80 mg daily | 15.7 | true | MSS | 2026-03-15T05:36:01.736336+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858767 | REC_0016427 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 4.1 | 84 | female | 2 | 7 | 5.4 | 2 | sotorasib 960 mg daily | 15.3 | true | MSS | 2026-03-15T05:36:01.736723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_653010 | REC_0016428 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 13.4 | 63 | female | 1 | 11 | 5 | 2 | entrectinib 600 mg daily | 24.5 | false | MSS | 2026-03-15T05:36:01.737084+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165398 | REC_0016429 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 14 | 9.7 | 71 | female | 1 | 16 | 5.9 | 5 | sotorasib 960 mg daily | 14.4 | true | MSS | 2026-03-15T05:36:01.737473+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_229518 | REC_0016430 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 13.4 | 85 | female | 2 | 11 | 4.8 | 6 | alectinib 600 mg BID | 7.7 | true | MSI-H | 2026-03-15T05:36:01.737874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957718 | REC_0016431 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 8.3 | 67 | female | 0 | 4 | 5.5 | 5 | osimertinib 80 mg daily | 13.8 | false | MSS | 2026-03-15T05:36:01.738268+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707255 | REC_0016432 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.6 | 65 | male | 0 | 16 | 2.5 | 3 | alectinib 600 mg BID | 11.4 | false | MSI-H | 2026-03-15T05:36:01.738667+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_520898 | REC_0016433 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 7.9 | 71 | female | 1 | 21 | 6.2 | 7 | osimertinib 80 mg daily | 6.9 | true | MSS | 2026-03-15T05:36:01.739267+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_291335 | REC_0016434 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 9.4 | 67 | female | 1 | 24 | 5.2 | 4 | sotorasib 960 mg daily | 10.1 | false | MSS | 2026-03-15T05:36:01.739690+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_578990 | REC_0016435 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 13.7 | 80 | male | 1 | 20 | 6.9 | 2 | pembrolizumab 200 mg q3w | 21.3 | false | MSI-H | 2026-03-15T05:36:01.740060+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736408 | REC_0016436 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 29 | 11.1 | 49 | male | 0 | 6 | 6.8 | 0 | osimertinib 80 mg daily | 19.5 | true | MSI-H | 2026-03-15T05:36:01.740596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858405 | REC_0016437 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 14.2 | 42 | female | 0 | 8 | 5.2 | 6 | osimertinib 80 mg daily | 12 | true | MSS | 2026-03-15T05:36:01.741024+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217975 | REC_0016438 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 19 | 15.2 | 64 | female | 0 | 8 | 7.2 | 6 | pembrolizumab 200 mg q3w | 9.2 | true | MSI-H | 2026-03-15T05:36:01.741450+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_372281 | REC_0016439 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 9.2 | 62 | male | 1 | 12 | 6 | 1 | pembrolizumab 200 mg q3w | 28.1 | true | MSS | 2026-03-15T05:36:01.741858+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819410 | REC_0016440 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 4.7 | 71 | female | 3 | 47 | 6.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.6 | false | MSS | 2026-03-15T05:36:01.742243+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_913460 | REC_0016441 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 32 | 6.7 | 68 | female | 1 | 33 | 4.3 | 2 | pembrolizumab 200 mg q3w | 19.2 | true | MSS | 2026-03-15T05:36:01.742619+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_259196 | REC_0016442 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 8.8 | 80 | female | 3 | 11 | 6.3 | 2 | entrectinib 600 mg daily | 12.2 | false | MSS | 2026-03-15T05:36:01.743014+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545025 | REC_0016443 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 33 | 7.8 | 71 | female | 2 | 10 | 5.1 | 7 | pembrolizumab 200 mg q3w | 13.5 | false | MSS | 2026-03-15T05:36:01.743402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_708088 | REC_0016444 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 24 | 11.8 | 67 | female | 1 | 25 | 4.7 | 0 | osimertinib 80 mg daily | 32.7 | true | MSS | 2026-03-15T05:36:01.743805+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146238 | REC_0016445 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 14.4 | 59 | male | 1 | 10 | 3.8 | 3 | alectinib 600 mg BID | 11.4 | false | MSS | 2026-03-15T05:36:01.744207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_964639 | REC_0016446 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 25 | 8.6 | 77 | female | 1 | 19 | 7.8 | 0 | alectinib 600 mg BID | 33 | true | MSS | 2026-03-15T05:36:01.744738+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858452 | REC_0016447 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 34 | 7.1 | 67 | female | 1 | 20 | 4 | 5 | osimertinib 80 mg daily | 15.2 | true | MSS | 2026-03-15T05:36:01.745184+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_635748 | REC_0016448 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 18.3 | 66 | male | 0 | 25 | 5 | 2 | alectinib 600 mg BID | 15.2 | true | MSI-H | 2026-03-15T05:36:01.745580+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_528347 | REC_0016449 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 5.8 | 76 | female | 2 | 14 | 6 | 4 | pembrolizumab 200 mg q3w | 11.7 | true | MSS | 2026-03-15T05:36:01.745947+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970267 | REC_0016450 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.4 | 74 | female | 0 | 15 | 6.2 | 4 | alectinib 600 mg BID | 14.6 | false | MSS | 2026-03-15T05:36:01.746321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498423 | REC_0016451 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 4.6 | 73 | female | 2 | 76 | 3 | 1 | carboplatin + paclitaxel + pembrolizumab | 7.3 | true | MSS | 2026-03-15T05:36:01.746683+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806512 | REC_0016452 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 17.3 | 71 | female | 1 | 19 | 3.3 | 5 | alectinib 600 mg BID | 15.3 | false | MSI-H | 2026-03-15T05:36:01.747017+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_403459 | REC_0016453 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 10.2 | 55 | male | 0 | 12 | 5.2 | 8 | alectinib 600 mg BID | 11 | true | MSS | 2026-03-15T05:36:01.747373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397283 | REC_0016454 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 1.5 | 73 | female | 1 | 17 | 4.6 | 4 | alectinib 600 mg BID | 10.3 | true | MSS | 2026-03-15T05:36:01.747696+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_973258 | REC_0016455 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 17 | 14.9 | 76 | male | 2 | 19 | 6.8 | 1 | sotorasib 960 mg daily | 16 | false | MSI-H | 2026-03-15T05:36:01.748038+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_923320 | REC_0016456 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 15.8 | 62 | female | 0 | 12 | 5.3 | 1 | alectinib 600 mg BID | 17.2 | true | MSS | 2026-03-15T05:36:01.748461+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423567 | REC_0016457 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 6.6 | 58 | male | 0 | 51 | 6.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.6 | false | MSS | 2026-03-15T05:36:01.748841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322181 | REC_0016458 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 8.9 | 46 | female | 0 | 11 | 5.6 | 3 | pembrolizumab 200 mg q3w | 10.1 | true | MSS | 2026-03-15T05:36:01.749237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_563195 | REC_0016459 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 9.1 | 58 | female | 1 | 11 | 6.1 | 5 | entrectinib 600 mg daily | 9.3 | true | MSS | 2026-03-15T05:36:01.749767+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_220926 | REC_0016460 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 10.1 | 63 | male | 1 | 13 | 4 | 4 | sotorasib 960 mg daily | 6.7 | false | MSI-H | 2026-03-15T05:36:01.750166+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_195707 | REC_0016461 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 14.7 | 61 | female | 0 | 18 | 4.2 | 6 | osimertinib 80 mg daily | 16.1 | true | MSS | 2026-03-15T05:36:01.750517+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_745328 | REC_0016462 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 10.5 | 43 | female | 0 | 17 | 3.3 | 5 | sotorasib 960 mg daily | 11.5 | true | MSI-H | 2026-03-15T05:36:01.750832+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_138653 | REC_0016463 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 10.3 | 72 | female | 2 | 10 | 7.2 | 6 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:01.751156+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_118038 | REC_0016464 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 8.1 | 70 | female | 1 | 10 | 8.9 | 2 | osimertinib 80 mg daily | 7.6 | false | MSS | 2026-03-15T05:36:01.751498+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802582 | REC_0016465 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 26 | 10.7 | 73 | female | 2 | 1 | 3.4 | 0 | osimertinib 80 mg daily | 15.4 | false | MSI-H | 2026-03-15T05:36:01.751845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_125304 | REC_0016466 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 9.3 | 70 | female | 3 | 15 | 5.1 | 2 | pembrolizumab 200 mg q3w | 29.9 | false | MSS | 2026-03-15T05:36:01.752275+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158694 | REC_0016467 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 14 | 11.9 | 59 | male | 1 | 5 | 7.5 | 8 | entrectinib 600 mg daily | 16.3 | true | MSI-H | 2026-03-15T05:36:01.752685+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306756 | REC_0016468 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 3 | 57 | male | 0 | 40 | 4.6 | 8 | pembrolizumab 200 mg q3w | 7.8 | true | MSS | 2026-03-15T05:36:01.753065+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842692 | REC_0016469 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 28 | 6.3 | 74 | female | 1 | 18 | 5.3 | 0 | alectinib 600 mg BID | 35.8 | false | MSS | 2026-03-15T05:36:01.753386+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748368 | REC_0016470 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 16.2 | 68 | female | 0 | 19 | 6.1 | 6 | alectinib 600 mg BID | 4 | false | MSS | 2026-03-15T05:36:01.753658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_131976 | REC_0016471 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 5.9 | 70 | female | 0 | 7 | 4.7 | 2 | pembrolizumab 200 mg q3w | 24.3 | false | MSS | 2026-03-15T05:36:01.753921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795536 | REC_0016472 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 17.9 | 65 | female | 1 | 21 | 7 | 2 | osimertinib 80 mg daily | 12.3 | false | MSI-H | 2026-03-15T05:36:01.754425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_972647 | REC_0016473 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 14.3 | 63 | female | 0 | 9 | 5 | 2 | pembrolizumab 200 mg q3w | 25 | true | MSS | 2026-03-15T05:36:01.754835+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616530 | REC_0016474 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 15 | 77 | female | 1 | 18 | 4.5 | 7 | sotorasib 960 mg daily | 11.4 | false | MSI-H | 2026-03-15T05:36:01.755189+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_759280 | REC_0016475 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 18.7 | 77 | female | 2 | 8 | 4.8 | 5 | sotorasib 960 mg daily | 13.6 | false | MSS | 2026-03-15T05:36:01.755530+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723866 | REC_0016476 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 8.2 | 81 | female | 2 | 16 | 5 | 4 | osimertinib 80 mg daily | 9.6 | true | MSS | 2026-03-15T05:36:01.755871+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_922316 | REC_0016477 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 14.7 | 71 | female | 3 | 18 | 6.5 | 3 | osimertinib 80 mg daily | 14.7 | false | MSI-H | 2026-03-15T05:36:01.756304+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293139 | REC_0016478 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 9.4 | 71 | female | 3 | 14 | 6.9 | 2 | sotorasib 960 mg daily | 21.5 | false | MSS | 2026-03-15T05:36:01.756672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_502882 | REC_0016479 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 11.6 | 80 | female | 2 | 11 | 4.4 | 2 | alectinib 600 mg BID | 19.4 | true | MSS | 2026-03-15T05:36:01.757003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_654613 | REC_0016480 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 6 | 57 | male | 1 | 36 | 5.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 5 | true | MSS | 2026-03-15T05:36:01.757336+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_471001 | REC_0016481 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 10.7 | 69 | male | 0 | 16 | 5.3 | 7 | sotorasib 960 mg daily | 13.8 | true | MSI-H | 2026-03-15T05:36:01.757685+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_917876 | REC_0016482 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 12.8 | 68 | female | 1 | 3 | 4.2 | 6 | osimertinib 80 mg daily | 18 | true | MSI-H | 2026-03-15T05:36:01.758091+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149378 | REC_0016483 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 9.7 | 73 | male | 2 | 18 | 4.5 | 7 | pembrolizumab 200 mg q3w | 8.3 | false | MSS | 2026-03-15T05:36:01.758483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_894769 | REC_0016484 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 13 | 43 | female | 0 | 19 | 3.6 | 2 | osimertinib 80 mg daily | 14 | false | MSS | 2026-03-15T05:36:01.758872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756850 | REC_0016485 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 10.9 | 76 | female | 1 | 9 | 7.2 | 2 | sotorasib 960 mg daily | 13.4 | false | MSI-H | 2026-03-15T05:36:01.759483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_162561 | REC_0016486 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 17.3 | 66 | female | 1 | 23 | 5.7 | 9 | entrectinib 600 mg daily | 7.8 | false | MSS | 2026-03-15T05:36:01.759900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449387 | REC_0016487 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 18.6 | 67 | female | 0 | 16 | 4.9 | 4 | pembrolizumab 200 mg q3w | 15.1 | true | MSS | 2026-03-15T05:36:01.760365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792761 | REC_0016488 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 12.3 | 78 | male | 1 | 14 | 6.5 | 3 | osimertinib 80 mg daily | 14.2 | true | MSI-H | 2026-03-15T05:36:01.760724+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252058 | REC_0016489 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 9.1 | 53 | male | 0 | 7 | 6 | 6 | entrectinib 600 mg daily | 14.4 | true | MSS | 2026-03-15T05:36:01.761084+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566846 | REC_0016490 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 10 | 70 | female | 2 | 6 | 6.9 | 5 | entrectinib 600 mg daily | 4 | true | MSI-H | 2026-03-15T05:36:01.761422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_326098 | REC_0016491 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 12 | 10.2 | 76 | female | 1 | 15 | 3.6 | 6 | sotorasib 960 mg daily | 16 | false | MSS | 2026-03-15T05:36:01.761754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_171931 | REC_0016492 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 6.3 | 56 | male | 0 | 11 | 5 | 6 | entrectinib 600 mg daily | 5.1 | true | MSS | 2026-03-15T05:36:01.762105+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697023 | REC_0016493 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 7.6 | 63 | female | 1 | 20 | 4.5 | 4 | osimertinib 80 mg daily | 8.9 | true | MSS | 2026-03-15T05:36:01.762451+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_810141 | REC_0016494 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 8.3 | 67 | female | 1 | 18 | 4 | 2 | entrectinib 600 mg daily | 28 | true | MSS | 2026-03-15T05:36:01.762807+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616549 | REC_0016495 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 6.2 | 64 | female | 0 | 11 | 6.5 | 1 | pembrolizumab 200 mg q3w | 20.7 | true | MSS | 2026-03-15T05:36:01.763216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_813360 | REC_0016496 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 11.4 | 80 | female | 2 | 11 | 4.8 | 5 | alectinib 600 mg BID | 8.4 | true | MSS | 2026-03-15T05:36:01.763598+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957779 | REC_0016497 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 5.8 | 62 | female | 1 | 18 | 6.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 9.6 | false | MSS | 2026-03-15T05:36:01.763980+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_472654 | REC_0016498 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 8.1 | 63 | female | 0 | 18 | 6.5 | 2 | entrectinib 600 mg daily | 16.6 | true | MSS | 2026-03-15T05:36:01.764629+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951495 | REC_0016499 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 7.6 | 69 | female | 1 | 59 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.1 | false | MSS | 2026-03-15T05:36:01.765090+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_651314 | REC_0016500 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.8 | 61 | female | 0 | 7 | 6.4 | 5 | sotorasib 960 mg daily | 12 | true | MSI-H | 2026-03-15T05:36:01.765518+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.